Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes

2018 ◽  
Vol 150 (1) ◽  
pp. 14-18 ◽  
Author(s):  
Dimitrios Nasioudis ◽  
Spyridon A. Mastroyannis ◽  
Benjamin B. Albright ◽  
Ashley F. Haggerty ◽  
Emily M. Ko ◽  
...  
2012 ◽  
Vol 22 (7) ◽  
pp. 1143-1149 ◽  
Author(s):  
Mika Mizuno ◽  
Hiroaki Kajiyama ◽  
Kiyosumi Shibata ◽  
Kimio Mizuno ◽  
Osamu Yamamuro ◽  
...  

BackgroundIt is controversial whether patients with stage I ovarian clear cell carcinoma (CCC) benefit from postoperative chemotherapy. This study was designed to evaluate the postoperative outcomes associated with the inclusion or exclusion of adjuvant therapy in these patients.MethodsA total of 185 patients who were treated for stage I CCC between 1991 and 2007 were retrospectively evaluated. All of the patients had received comprehensive surgical staging, and their condition had been diagnosed by a central pathological review system. Only one patient with stage IB was excluded from this study.ResultsMedian follow-up time was 62 months (range 7–191 months). Median age was 52 years (30–75 years). There were 41, 93, and 50 patients in stage IA, intraoperative capsule ruptured IC (rupture-IC), and all other-IC groups, respectively. The 5-year recurrence-free survival rates for the substage were 97.6%, 87.8%, and 70.4% (P < 0.001), respectively. Among 134 patients consisting of those in the stage IA and rupture-IC groups, 91 patients received adjuvant chemotherapy (AC) and 43 patients did not (non-AC). There was no significant survival difference in each substage group between the non-AC and AC groups in 5-year recurrence-free survival rate (stage IA, 100% vs 93.8%; rupture-IC, 94.1% vs 86.6%). Multivariate analysis demonstrated that there was no significant prognostic factor for both recurrence and survival among the IA and rupture-IC groups. Postoperative therapy, regimen, and chemotherapy cycles were not significantly affected.ConclusionsThis study indicates that adjuvant chemotherapy does not contribute to the improving prognosis of stage IA ovarian CCC. Whereas the histological type is CCC, the routine adjuvant chemotherapy after comprehensive surgical staging may be unnecessary for patients with at least stage IA.


2017 ◽  
Vol 147 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Liat Hogen ◽  
Harry Brar ◽  
Allan Covens ◽  
Dina Bassiouny ◽  
Marcus Q. Bernardini ◽  
...  

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16577-e16577
Author(s):  
Yuji Takei ◽  
Hiroyuki Fujiwara ◽  
Shizuo Machida ◽  
Akiyo Taneichi ◽  
Suzuyo Takahashi ◽  
...  

2021 ◽  
Vol 19 (2) ◽  
pp. 172-180
Author(s):  
Soumyajit Roy ◽  
Paul Hoskins ◽  
Anna Tinker ◽  
Harinder Brar ◽  
Gale Bowering ◽  
...  

Background: Adjuvant treatment in early ovarian clear cell carcinoma (OCCC) is not yet standardized. The objective of this population-based study was to compare the outcome of patients with early OCCC treated with adjuvant chemotherapy versus chemoradiotherapy (chemoRT) and evaluate the association of adjuvant radiotherapy regimens (whole abdominal radiotherapy [WART] versus pelvic nodal radiotherapy [PRT]) with outcome. Patients and Methods: Chart review was conducted to identify patients with stage I and II OCCC with complete information on staging. Patients with stage IA, IB, or IC OCCC purely resulting from capsular rupture were excluded because the provincial protocol does not recommend adjuvant treatment. Results: Overall, 403 patients were identified and 343 received adjuvant treatment, of whom 255 had stage IC or II OCCC and 153 were eligible for final analysis. On Cox multivariable regression, receipt of chemoRT (n=90) was associated with an improvement in failure-free survival (FFS) (hazard ratio [HR], 0.57; 95% CI, 0.34–0.94) compared with chemotherapy alone (n=63). Use of chemoRT also resulted in 54% reduction in the cumulative incidence of cancer-specific mortality (subdistribution HR, 0.46; 95% CI, 0.24–0.89). However, there was no significant difference in the HR for overall survival (OS) between the chemoRT (HR, 0.70; 95% CI, 0.43–1.13) and chemotherapy group. Relative to chemotherapy + WART (chemo-WART), chemotherapy + PRT (chemo-PRT) was not associated with any significant difference in HR for FFS (HR, 1.34; 95% CI, 0.40–4.44) or OS (HR, 1.13; 95% CI, 0.37–3.46). Conclusions: Adjuvant chemoRT was associated with a lower risk of failure compared with chemotherapy alone. However, there was no difference in OS between the adjuvant chemotherapy and chemoRT regimens. Additionally, no significant difference in terms of FFS or OS was found between the chemo-WART and chemo-PRT groups.


2012 ◽  
Vol 22 (4) ◽  
pp. 573-578 ◽  
Author(s):  
Toshio Takada ◽  
Haruko Iwase ◽  
Chiaki Iitsuka ◽  
Hidetaka Nomura ◽  
Kimihiko Sakamoto ◽  
...  

2016 ◽  
Vol 47 (2) ◽  
pp. 170-174 ◽  
Author(s):  
Tomoko Yoshihama ◽  
Akira Hirasawa ◽  
Hiroyuki Nomura ◽  
Tomoko Akahane ◽  
Yoshiko Nanki ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document